samedan logo
 
 
spacer
home > pmps > summer 2002 > the polish pharmaceutical industry - dynamic growth in a challenging legal environment
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Polish Pharmaceutical Industry - Dynamic Growth in a Challenging Legal Environment

The Polish pharmaceutical industry has undergone tremendous change during the 12 years of the economical and political transformation that has taken place since the fall of communism. The privatisation of the state-owned pharmaceutical producers and the fast-changing legal environment - particularly influenced by the ongoing accession negotiations with the European Union - form the landscape in which Polish and foreign producers currently operate.

Dynamic Growth

The Polish pharmaceutical market has been growing notably in the last few years. Sales of pharmaceuticals have risen from approximately US$500 million to US$2,500 million in 2001, with the year-on-year growth of sales recorded in 2001 equal to 17 per cent. Some forecasts envisage the pharmaceutical market equaling US$4,500 million in 2005.

The Polish market is characterised by fairly large unit sales per inhabitant (34 per inhabitant compared with 27 in Italy), but a relatively low value of each sale (approximately US$1.6 per sale compared with US$4.9 in France). Given the fact the typical Pole is fairly interested in his/her health, it can be expected that the value of each sale will rise in the future as the society becomes more affluent. There are approximately 200 pharmaceutical firms active in Poland, most of them relatively small, and overall employing around 20,000 people.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Wladyslaw Rzycki, Attorney at White & Case Wladyslaw Rzycki is a US and Polish Lawyer with experience in many tax, commercial and financial transactions in the US, including structuring and planning for multinationals, pharmaceutical companies, e-commerce companies and venture capital investment offshore.
Prior to joining White & Case in June 2001, Wladyslaw worked at the law firm Mayer, Brown & Platt in Chicago where his practice focused on mergers and acquisitions corporate taxation, international taxation and taxation of financial instruments.

spacer
Wladyslaw Rzycki
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IBM Research and Arctoris Accelerate Closed Loop Drug Discovery with AI and Cloud

Oxford and Zurich 13 September 2021 Life Science Newswire Today, IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry.
More info >>

White Papers

High Containment FIBCs Offer a Safe and Cost Effective Alternative to their Rigid Counterparts

ILC Dover

As the need for powder containment and manufacturing in accordance with cGMP standards has grown over the years, companies have sought new alternatives to rigid IBCs. Recently high containment Flexible Intermediate Bulk Containers (FIBCs) have emerged which offer an alternative that provides both powder containment and the benefits of shipping with flexibles.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement